razoxane 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| benzodioxane derivatives | 4031 | 21416-67-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An antimitotic agent with immunosuppressive properties.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D050256 | Antimitotic Agents |
| MeSH PA | D000970 | Antineoplastic Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Doxorubicin Induced Cardiomyopathy | indication | ||
| Extravasation Injury from Anthracycline Injection | indication | ||
| Impaired renal function disorder | contraindication | 197663003 | |
| Bone marrow depression | contraindication | 307762000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.61 | acidic |
| pKa2 | 10.22 | acidic |
| pKa3 | 6.83 | Basic |
| pKa4 | 2.83 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| N0000006134 | NUI |
| D08471 | KEGG_DRUG |
| C0034738 | UMLSCUI |
| CHEBI:50225 | CHEBI |
| CHEMBL444186 | ChEMBL_ID |
| D011929 | MESH_DESCRIPTOR_UI |
| 30623 | PUBCHEM_CID |
| 3675 | INN_ID |
| 5AR83PR647 | UNII |
| 196454 | RXNORM |
| 004030 | NDDF |
| 387518009 | SNOMEDCT_US |
| 90346006 | SNOMEDCT_US |
Pharmaceutical products:
None